Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Calcium-dependent activator protein for secretion 2 (CADPS2)
- Target
- CADPS2
- Molecular classification
- Protein, Calcium-binding protein, Synaptic vesicle priming protein, Dense-core vesicle exocytosis regulator
01
Overview
Calcium-dependent activator protein for secretion 2 (CADPS2) is a member of the CAPS protein family, characterized by calcium-binding and regulatory roles in the exocytosis of synaptic and dense-core vesicles within neurons and neuroendocrine cells. CADPS2 facilitates activity-dependent release of neurotransmitters and neuropeptides, as well as neurotrophins such as brain-derived neurotrophic factor (BDNF) and neurotrophin-3, thereby influencing neuronal survival, synaptic formation, development, and plasticity. It acts upstream of vesicle fusion and is essential for the proper trafficking and maturation of vesicles, particularly in dopamine neurons of the midbrain. Alterations in CADPS2 have been implicated in neurodevelopmental and neurodegenerative diseases, including autism spectrum disorder and Parkinson’s disease, possibly through impaired vesicle exocytosis and disrupted neurotrophin signaling. There are multiple transcript variants and isoforms; dysregulated expression or splicing may be used as a biomarker for certain conditions. CADPS2 is a protein-coding gene and is expressed throughout the nervous system, especially in dopaminergic neurons.
- Other names
- CAPS2KIAA1591CAPS-2calcium-dependent secretion activator 2Ca2+-dependent activator protein for secretion 2Calcium-dependent activator protein for secretion 2Ca2+ dependent secretion activator 2
02
Mechanism of action
Drugs targeting CADPS2 would hypothetically modulate calcium-dependent vesicle exocytosis, affecting neurotransmitter or neurotrophin release
03
Biological functions
Exocytosis of neurotransmitter/neuropeptide-containing vesiclesSynaptic vesicle primingNeurotrophin release (e.g. BDNF, neurotrophin-3)Regulation of neuronal survivalSynaptic developmentInfluences synaptic plasticityCell differentiation during cerebellar development
04
Disease associations
Autism spectrum disorderParkinson’s diseaseHypogonadotropic hypogonadism (with or without anosmia)Possible role in neurodegenerative and neurodevelopmental disorders
05
Safety considerations
Modulation of CADPS2 could impact neurotransmitter/neurotrophin release, with possible effects on behavior, neurodevelopment, and neurodegeneration; risks include synaptic dysfunction and altered neuronal survival
06
Biomarkers
Potential changes in CADPS2 expression or splicing associated with autism spectrum disorder and Parkinson’s disease
Beyond the preview
Go deeper on Calcium-dependent activator protein for secretion 2 (CADPS2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Calcium-dependent activator protein for secretion 2 (CADPS2).